Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

Status Completed

Clinical Trial Summary

The study will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose. Secondary assessments will examine the effect of these nutritional supplements versus placebo on inflammation, fasting lipids, HbA1C, and fructosamine, longer term metabolic markers of risk in diabetes.

Clinical Trial Description

This will be a 28-day randomized controlled trial of the effects of a nutraceutical preparation on glycemic control in non-diabetic individuals with impaired glucose tolerance (IGT). IGT will be defined by American Diabetes Association criteria, as outlined in the list of inclusion and exclusion criteria (copy attached). There will be two active treatment arms and a placebo arm (3 arms total, n=12 completed subjects per arm). Following screening for inclusion/exclusion criteria and obtaining informed consent, subjects will be enrolled in the study and provided instructions to maintain their usual dietary pattern and physical activity level. If recent physical examination and medical history are not available; H&P will be conducted and recorded for each enrolled subject. Subjects will be instructed to follow a 12-hour fast starting on day -1, and on the morning of day 0 fasting blood is drawn for analyses indicated below and the supplements are distributed. Supplements are distributed using a blinding protocol and a variable, known pill allotment in order to assess compliance via standard pill counts. Pill bottles and all unused supplements are returned at seven day intervals, with new supplies being distributed at that time. Fasting blood samples are obtained on days 0, 7, 14 and 28. Samples from each day are analyzed for glucose and insulin. Samples from days 0, 14 and 28 are also analyzed for fructosamine, C-peptide, glucagon and F2-isoprostanes. A75 g oral glucose tolerance test administered on days 0 and 28. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01593605
Study type	Interventional
Source	Vanderbilt University
Contact
Status	Completed
Phase	N/A
Start date	February 2012
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05354245` - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL)	N/A
Completed	`NCT04088461` - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine	Phase 4
Completed	`NCT02621060` - Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance	Phase 2
Completed	`NCT01488279` - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy	N/A
Completed	`NCT01521312` - ACute and Chronic Effects of Saxagliptin	Phase 2
Completed	`NCT01559896` - Egg Protein Hydrolysate and Vascular Function	N/A
Completed	`NCT01030978` - Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program	N/A
Completed	`NCT00573781` - Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism	Phase 2
Terminated	`NCT00846521` - Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity	Phase 4
Completed	`NCT00241072` - Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance	Phase 4
Completed	`NCT00536250` - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth	N/A
Completed	`NCT02254317` - Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance	N/A
Completed	`NCT03764423` - Health Effects of Salmon Fishmeal in Humans	N/A
Recruiting	`NCT05347030` - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population	N/A
Active, not recruiting	`NCT04341571` - Effect of Probiotics Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes.	Phase 2
Completed	`NCT02700334` - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes	Phase 4
Active, not recruiting	`NCT01933529` - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)	Phase 2
Completed	`NCT02135172` - Breaks in Sedentary Time and Glucose Regulation in Women	N/A
Active, not recruiting	`NCT01841229` - Effect of Ginseng on Glycemic Control	N/A
Completed	`NCT02248272` - Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.